medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2007, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2007; 54 (3)

Acute coronary syndrome: Markers of myocardium lesion

Barba EJR

Language: Spanish
References: 80
Page: 116-135
PDF size: 435.36 Kb.


ABSTRACT

Nowadays cardiovascular disease (CVD) represents one of the main problems with public health on a world-wide level, because of this it is necessary to count with a series of diagnosis that allow the opportune recognition of ischemic myocardic in order to establish opportune treatment and prevent a major ischemic damage as well as diminish morbid-mortality, which translates to economic resource savings. It is also important that these diagnostic tools allow to recognize each and every it is «healthy» individual but with risk factors that would develop into an acute coronary syndrome. The present article consists in a review of the «biomarkers» of myocardic leasures frequently used as a power predictor for coronary disease.


REFERENCES

  1. Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.

  2. Vargas RA, González CO, Díaz VV. Dolor torácico agudo de origen cardiaco. Médica Sur 2002; 9 (1): 8-14.

  3. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.

  4. Mogelvang R, Scharling H, Jensen JS. A simple linear model for the effect of changes in metabolic risk on coronary heart disease. J Inter Med 2006; 259: 561-568.

  5. George K, Alberti MM, Zimmet P, Shaw J. The metabolic syndrome- a new worldwide definition. Lancet 2005; 366 (24): 1059-1062.

  6. Haffner SM, Lehto S, Rönnemaa T, Pyöräla K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.

  7. Reaven G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation 2005; 112: 3030-3032.

  8. Roldán TI, Baello MP, Sevilla TB, Sanz AS, Salim MM et al. Valor pronóstico de la troponina T en pacientes hospitalizados con angina o infarto sin elevación del segmento ST. Rev Esp Cardiol 2003; 56 (1): 35-42.

  9. Keffer HJ. Myocardial markers of injury. evolution and insights. Am J Clin Pathol 1996; 105: 305-320.

  10. Svensson L, Axelsson C, Nordalender R, Herlitz J. Elevation of biochemical markers for myocardial damage prior to hospital admission in patients with acute chest pain or other symptoms raising suspicion of acute coronary syndrome. J Inter Med 2003; 253: 311-319.

  11. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes. moving toward a multimarker strategy. Circulation 2003; 108: 250-252.

  12. Villegas ED, Fariña NML, Poseer PL, Ramos MH. Utilidad pronóstica de niveles elevados de troponina T en los SCA sin elevación persistente del segmento ST. Revista de Posgrado de la VIa Cátedra de Medicina 2004; 137: 12-14.

  13. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998; 98: 1853-1859.

  14. Mainet D, Sánchez L, Nazábal M, Echeverría M, Sorell L. Clonación, expresión y purificación de la troponina I cardiaca humana y su fragmento aminoterminal en Escherichia coli. Biotecnología Aplicada 2000; 17: 16-22.

  15. Serdar MA, Tokgoz S, Metinyurt G, Tapan S, Erinet K et al. Effect of macro-creatine kinase and increased creatine kinase BB on the rapid diagnosis of patients with suspected acute myocardial infarction in the Emergency Department. Mil Med 2005; 170 (8): 648-652.

  16. James SK, Lindalh B, Siegbahn A, Stridsberg M, Venge P et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy. Circulation 2003; 108: 275-281.

  17. Mainet GD, Sorell GL, Torres MB. La troponina I cardiaca: marcador bioquímico de elección del daño miocárdico. Biotecnología Aplicada 2000; 17: 77-84.

  18. Ramos CMA, Sánchez BJJ, Basave RN, Rangel AA, Medécigo MJ et al. Prueba de troponina T cardiaca en el diagnóstico temprano de infarto agudo del miocardio. Rev Mex Cardiol 2003; 14 (3): 81-85.

  19. deFilippi ChR, Tocchi M, Parmar RJ, Rosanio S, Abreo G et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: Angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol 2000; 35 (7): 1827-1834.

  20. Hollander JE. The future of cardiac biomarkers. New concepts and emerging technologies for emergency physicians. Emergency Medicine Cardiac Research Education Group 2005; 4: 1-6.

  21. Newby LK, Storrow AB, Gibler B, Garvey JL, Tucker JF et al. Bedside multimarker testing for risk stratification in chest pain units. The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001; 103: 1832-1837.

  22. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.

  23. Gibler WB, Blomkalns AL. Point-of-Care testing for cardiac biomarkers in the ED: a blueprint for implementation. Emergency Medicine Cardiac Research Education Group 2006; 1: 1-10.

  24. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH et al. Cardiac-specific troponin levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-1349.

  25. Adams III JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993; 88 (2): 750-763.

  26. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.

  27. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.

  28. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344 (26): 1959-1965.

  29. Ridker PM, Hennekens CH, Burning JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.

  30. Ridker PM, Rifai N, Rose L, Burning JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347 (20): 1557-1565.

  31. Nissen SE, Tuzcu M, Schoenhagen P, Crowe T, Sasiela WJ et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.

  32. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG et al. Elevated levels of C-reactive protein at discharge in patients unit instable angina predict recurrent instability. Circulation 1999; 99: 855-860.

  33. Ridker PM. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.

  34. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.

  35. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.

  36. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.

  37. Epstein FH. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340 (2): 115-126.

  38. Vatus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902-912.

  39. Adams III JE, Bodor GS, Dávila-Román VG, Delmez JA, Apple FS et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88: 101-106.

  40. ver Elst KM, Spapen HD, Nguyen DN, Garbar Ch, Huyghens LP, Gorus FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clinical Chemistry 2000; 46 (5): 650-657.

  41. Dierkes J, Domröse U, Westphal S, Ambrosch A, Bosselmann HP et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000; 102: 1964-1969.

  42. Löwbeer C, Stenvinkel P, Pecoits-Filho R, Heimbürger O, Lindholm B et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. J Inter Med 2003; 253: 153-160.

  43. Kennon S, Price CP, Mills PG, MacCallum PK, Cooper J et al. Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markers. Heart 2003; 89: 36-41.

  44. Capdevilla C, Portolés M, Hernández A, Pallarés V, Cosin J. La troponina T como posible marcador del daño miocárdico menor. Su aplicación en el miocardio aturdido y en la isquemia silente. Rev Esp Cardiol 2001; 54: 580-591.

  45. Murphy MJ, Berding CB. Use of measurements of myoglobin and cardiac troponins in the diagnosis of acute myocardial infarction. Critical Care Nurse 1999; 19 (1): 58-66.

  46. Adams JE, Sicard GA, Allen BT, Bridwell KH, Lenke LG et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330: 670-674.

  47. Pruszozyk P, Bochowioz A, Torbicki A, Szulc M, Kurzyna M et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123: 1947-1952.

  48. Masson JF, Obando L, Beudoin S, Booksh K. Sensitive and real-time fiber-optic-based surface plasmon resonance sensors for myoglobin and cardiac troponin I. Talanta 2004; 62: 865-870.

  49. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002; 346: 2047-2052.

  50. Apple FS, Murakami MAM, Pearce LA, Herzog ChA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-2945.

  51. Pendino JC. Péptidos natriuréticos. Fisiología aplicada a la práctica clínica. Clínica-UNR.org 2006.

  52. Felker GM, Peterson JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006; 175 (6): 611-617.

  53. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signaling. Br J Pharmacol 2003; 139: 1289-1296.

  54. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.

  55. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345 (14): 1014-1021.

  56. Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1347-1351.

  57. Pintor E, Fernández-Durango R, Crespo A, Pieltain R, Pedradas JM et al. Niveles endoteliales y auriculares del péptido natriurético después de la angioplastia coronaria transluminal percutánea. Cardiovascular Risk Factors 1999; 8 (4): 221-224.

  58. Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40 (4): 718-722.

  59. Greig D, Castro P, Ferrada M, Lim J, López C et al. Niveles de péptido natriurético cerebral y su relación con capacidad funcional y hemodinamia pulmonar en pacientes con hipertensión pulmonar primaria. Rev Med Chile 2006; 134: 299-304.

  60. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-2792.

  61. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.

  62. Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47 (1): 52-60.

  63. Muñoz AS. Paradoja actual de la insuficiencia cardiaca: prevalencia creciente a pesar de notables avances en el tratamiento. Gac Med Caracas 2002; 110 (4): 465-473.

  64. Cowie MR, Méndez GF. BNP and congestive heart failure. Curr Probl Cardiol 2003: 264-311.

  65. König D, Schumacher YO, Lothar H, Andreas S, Aloys B, Hans-Hermann D. Myocardial stress after competitive exercise in professional road cyclists. Med Sci Sports Exerc 2003; 35 (10): 1679-1683.

  66. Maisel A. The coming of age of natriuretic peptides. J Am Coll Cardiol 2006; 47 (1): 61-64.

  67. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure. What´s next? Circulation 2002; 105: 2328-2331.

  68. Hernández MA, Miguelañez DM, Escobar CC, Blanco TB, Marín I et al. Utilidad del péptido natriurético BNP en la evaluación de pacientes con insuficiencia cardiaca tratados con sincronización cardiaca. Rev Esp Cardiol 2004; 57 (4): 299-305.

  69. Troughton RW, Frampton ChM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guide by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.

  70. Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J et al. Detection of left ventricular enlargement and impaired systolic function with plasma N- terminal pro brain natriuretic peptide concentrations. Am Heart J 2002; 143: 923-929.

  71. Berger R, Huelsman M, Strecker K, Bojic A, Moser P et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397.

  72. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38 (7): 1934-1941.

  73. Omland T, Richards AM, Wergeland R, Vik-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005; 95: 24-28.

  74. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-1492.

  75. Svensson L, Axelsson C, Nordlander R, Herlitz J. Prognostic value of biochemical markers, 12-lead ECG and patient characteristics amongst patients calling for an ambulance due to a suspected acute coronary syndrome. J Inter Med 2004; 255: 469-477.

  76. Ulecia MMA, Selles GF, Cantero HJ, Torres RJM, Cano PD. Troponina I y creatincinasa-MB como evaluación de reperfusión eficaz tras fibrinólisis en el infarto agudo del miocardio. Rev Fed Arg Cardiol 2002; 31: 413-420.

  77. The Joint European Society of Cardiology/ American College of Cardiology Committee. Myocardial Infarction Redefined-A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36 (3): 959-969.

  78. Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochiman JS et al. Guidelines for unstable angina. J Am Coll Cardiol 2000; 36 (3): 970-1062.

  79. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000; 36: 679-684.

  80. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the center for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499-511.




2020     |     www.medigraphic.com